<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Maharaj AV</submitter><funding>Queen Mary University of London</funding><funding>Queen Mary University of London (Queen Mary)</funding><funding>National Institute for Health Research (NIHR)</funding><funding>Wellcome Trust</funding><pagination>8420</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11439042</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>Postnatal growth failure is often attributed to dysregulated somatotropin action, however marked genetic and phenotypic heterogeneity exist. We report five patients from three families who present with short stature, immune dysfunction, atopic eczema and gastrointestinal pathology associated with recessive variants in QSOX2. QSOX2 encodes a nuclear membrane protein linked to disulphide isomerase and oxidoreductase activity. Loss of QSOX2 disrupts Growth hormone-mediated STAT5B nuclear translocation despite enhanced Growth hormone-induced STAT5B phosphorylation. Moreover, patient-derived dermal fibroblasts demonstrate Growth hormone-induced mitochondriopathy and reduced mitochondrial membrane potential. Located at the nuclear membrane, QSOX2 acts as a gatekeeper for regulating stabilisation</pubmed_abstract><journal>Nature communications</journal><pubmed_title>QSOX2 Deficiency-induced short stature, gastrointestinal dysmotility and immune dysfunction.</pubmed_title><pmcid>PMC11439042</pmcid><funding_grant_id>NIHR300098</funding_grant_id><funding_grant_id>MEAG2C4R</funding_grant_id><pubmed_authors>Elfeky R</pubmed_authors><pubmed_authors>Ishida M</pubmed_authors><pubmed_authors>Joensuu A</pubmed_authors><pubmed_authors>Hwa V</pubmed_authors><pubmed_authors>Andrews A</pubmed_authors><pubmed_authors>Rybak A</pubmed_authors><pubmed_authors>Maharaj AV</pubmed_authors><pubmed_authors>Joshi A</pubmed_authors><pubmed_authors>McGuffin LJ</pubmed_authors><pubmed_authors>Storr HL</pubmed_authors><pubmed_authors>O'Toole EA</pubmed_authors><pubmed_authors>Kantojarvi K</pubmed_authors><pubmed_authors>Elmslie F</pubmed_authors><pubmed_authors>Jia RY</pubmed_authors><pubmed_authors>Perry JRB</pubmed_authors></additional><is_claimable>false</is_claimable><name>QSOX2 Deficiency-induced short stature, gastrointestinal dysmotility and immune dysfunction.</name><description>Postnatal growth failure is often attributed to dysregulated somatotropin action, however marked genetic and phenotypic heterogeneity exist. We report five patients from three families who present with short stature, immune dysfunction, atopic eczema and gastrointestinal pathology associated with recessive variants in QSOX2. QSOX2 encodes a nuclear membrane protein linked to disulphide isomerase and oxidoreductase activity. Loss of QSOX2 disrupts Growth hormone-mediated STAT5B nuclear translocation despite enhanced Growth hormone-induced STAT5B phosphorylation. Moreover, patient-derived dermal fibroblasts demonstrate Growth hormone-induced mitochondriopathy and reduced mitochondrial membrane potential. Located at the nuclear membrane, QSOX2 acts as a gatekeeper for regulating stabilisation</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-06-02T23:03:09.721Z</modification><creation>2025-04-04T19:38:26.188Z</creation></dates><accession>S-EPMC11439042</accession><cross_references><pubmed>39341815</pubmed><doi>10.1038/s41467-024-52587-w</doi></cross_references></HashMap>